ArticleSafety and health at work2025
Development of Korean CARcinogen EXposure: IARC Group 2A Carcinogens.
Article in Safety and health at work, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Reliable exposure data are critical for occupational cancer prevention and epidemiological studies. We developed the Korean CARcinogen EXposure (K-CAREX) to provide exposure prevalence and intensity for 20 carcinogens classified as Group 1 by the International Agency for Research on Cancer (IARC). This study extends K-CAREX to include IARC Group 2A agents. Methods: National data sources, including the Work Environment Measurement Database (WEMD), Special Health Examination Database (SHED), and Work Environment Condition Survey (WECS), provided basic exposure data. A stepwise estimation approach was employed to refine exposure prevalence estimates by industry, derived from the WEMD, SHED, and WECS. WEMD was used to estimate exposure intensity by industry, whereas SHED was used to assess exposure prevalence by occupation. Matched data, representing workers who wore samplers and underwent health examinations for the same carcinogen in the same year, were used to estimate exposure intensity by occupation. Results: A total of 18 IARC Group 2A agents were included. Exposure prevalence was estimated for all 18 carcinogens by industry, and exposure intensity was estimated for 16. The number of exposed workers was estimated, with 162,153 workers exposed to lead, for example. Exposure prevalence and intensity were also assessed for 18 and 16 carcinogens, respectively, by occupation. Conclusion: The K-CAREX database was developed to estimate exposure prevalence and intensity by industry and occupation for 18 IARC Group 2A agents. These findings provide valuable data for cancer prevention and epidemiological studies. Future work may expand K-CAREX to include IARC Group 2B agents and other carcinogenic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.